Quick Facts: Therapeutic Domains

• Supports the management of postherpetic neuralgia in adults.
• Used as an adjunct therapy for partial onset seizures in adults and children.

---

Gabapin 300 is a prescription medication indicated for the management of certain neurological conditions. The primary therapeutic uses of this medicine are supported by clinical experience.

Key Therapeutic Domains

1. Postherpetic Neuralgia (PHN): Gabapin 300 may help relieve nerve pain following an outbreak of shingles (herpes zoster virus). This condition involves discomfort and sensitivity that may persist long after the initial rash has cleared. The medication supports the reduction of this chronic nerve-related pain.

2. Epilepsy: The compound is utilized as adjunctive therapy, meaning it is used alongside other medicines, to support the control and prevention of partial onset seizures. This use includes adults and pediatric patients aged three years and older who have epilepsy. It is important to note that the medication is intended to assist in seizure control and is not considered a cure for the condition.

Eligibility Map: Who can and cannot use Gabapin 300 — Official Regulatory Information

Eligibility Scope	Official Regulatory Classification/Rule
Contraindicated (Must Not Use)	Patients with known hypersensitivity or allergic reaction to gabapentin or any component of the formulation.
Use Allowed (Age)	Adults for both approved uses; Pediatric patients 3 years of age and older for partial onset seizures.
Use Not Established (Age Restriction)	For the treatment of partial onset seizures, safety and effectiveness have not been established in children younger than 3 years of age.
Use Restricted (Condition)	Patients with impaired renal function (low creatinine clearance) must have their dosage reduced and adjusted according to the degree of impairment.
Not Studied (Condition/Age)	Use in pediatric patients with compromised renal function has not been studied.

---

The official regulatory documents define a clear constraint on the use of gabapentin, primarily by contraindicating its use in individuals with a documented hypersensitivity to the drug substance or excipients. Eligibility is also structured by age, as the drug's safety profile is officially not established for treating partial seizures in children under 3 years old, and for treating postherpetic neuralgia in any pediatric patient. Furthermore, because the drug is eliminated almost entirely by the kidneys, patients with impaired renal function are only eligible with a mandated, medically supervised dose adjustment to prevent accumulation and toxicity.

Interactions with other medicines and products

Interaction Scope

Gabapin 300's official interaction profile primarily involves pharmacodynamic additive effects and pharmacokinetic interference with absorption. Interactions are documented for substance categories including opioids (e.g., morphine), alcohol, and other CNS depressants such as benzodiazepines and sedating antihistamines. The medication is also known to interact with specific types of antacids containing aluminum and/or magnesium. Due to its negligible metabolism in humans, no clinically significant interactions mediated by the Cytochrome P450 enzyme system are documented in regulatory labeling.

---

Interaction Classifications (High-Level)

The most critical interaction classified by regulatory bodies is the pharmacodynamic reinforcement with central nervous system depressants. This is officially noted as a significant risk for severe respiratory depression and profound sedation. A key pharmacokinetic restriction relates to the co-administration of aluminum and/or magnesium-containing antacids, which reduce the systemic exposure of Gabapentin.

---

Official Interaction Statements

• Co-administration with opioids and other CNS depressants increases the risk of severe breathing difficulties and deep sedation, a risk noted to be higher for elderly patients and those with underlying respiratory impairment.
• Antacids containing aluminum or magnesium reduce Gabapentin's bioavailability. Administration must be separated by at least two hours to mitigate this documented pharmacokinetic effect.
• The substance Cimetidine is documented to slightly reduce Gabapentin's apparent renal clearance.

️ How Gabapin 300 Works

Gabapin 300's mechanism of action involves the targeted modulation of nerve activity within the central and peripheral nervous systems. The active ingredient, Gabapentin, works by binding with high affinity to the mathbfalpha2-delta subunit of certain Voltage-Gated Calcium Channels (VGCCs).

This binding interaction reduces the functional expression and trafficking of these channels to the nerve cell surface, thus limiting the calcium ion influx into the presynaptic nerve ending. This molecular action initiates a cascade that results in a functional reduction of excitatory neurotransmitter release, such as glutamate, into the synapse.

By reducing the flow of these stimulating chemical messengers, the drug alters the membrane potential and reduces signal propagation between neurons in highly active pathways. The resulting effect is a modulation of excessive nerve signaling, altering physiological responses associated with increased neuronal activity.

Gabapentin (the active ingredient in Gabapin 300 capsules) is an immediate-release medicine for oral administration only. Clinical guidelines detail a structured approach to dosing, including titration and adjustments for specific patient groups.

---

Official Administration Guidelines

Feature	Instruction
Route & Timing	Oral use. Can be taken with or without food. Capsules should be swallowed whole.
Dosing Schedule (Adults)	Treatment typically begins with a titration (gradual increase) over the first three days. The maintenance dose for partial seizures is often 900 mg to 3600 mg per day, divided into three doses.
Frequency	The total daily dose must be administered in three divided doses (TID). The maximum time interval between doses should not exceed 12 hours.
Renal Adjustment	Dose adjustments are required for patients with reduced kidney function (based on creatinine clearance) and for patients undergoing hemodialysis.
Antacid Condition	If antacids containing aluminum or magnesium are taken, gabapentin must be administered at least two hours later.
Discontinuation	The medicine should not be stopped suddenly. Dose reduction or discontinuation must be carried out gradually over a minimum of one week.

---

This structured protocol ensures a consistent level of medication is maintained in the body, requiring doses to be spaced evenly throughout the day to prevent the maximum 12-hour interval from being breached. Established protocols provide specific starting and maintenance dose ranges for both adult and pediatric populations, as well as necessary modifications for renal impairment.

Research Evidence / Overview of Studies for Gabapin 300

The available information on Gabapin 300 (gabapentin) comes from various research studies, primarily focusing on its studied indications. This summary describes the type of evidence that has been gathered, the outcomes that were measured, and the limitations noted by researchers, without making claims about effectiveness or giving medical advice.

Evidence for Use in Partial-Onset Seizures (Adjunctive Therapy)

Research examining the use of gabapentin for partial-onset seizures primarily involved short-term, randomized controlled trials (RCTs). These studies included patients already taking other anti-seizure medications. Researchers used these studies to monitor and report how seizure frequency was measured over a defined time interval and to measure the proportion of participants whose seizure counts were categorized as reduced.

Studies described patterns observed in these trials, detailing how subjects' seizure counts were measured when gabapentin was used compared to when a placebo (an inactive substance) was used. The evidence contributes to understanding symptom patterns over the defined time intervals studied.

Evidence for Use in Postherpetic Neuralgia (PHN)

For postherpetic neuralgia, the evidence is largely built upon short-term randomized, placebo-controlled trials. These studies were applied in research exploring patient-reported experiences of pain that remains after a shingles outbreak. The main outcomes measured were changes in subjective pain intensity scores, measurements of sleep quality, and how patients perceived their symptoms compared to the start of the study.

Trials reported measurements of the mean change in pain scores from the baseline measurement at various short-term time points. Study findings described documented changes in patient-reported measures of sleep disturbance and how the condition was perceived to affect the overall quality of life during the trial period.

What is Still Uncertain About Gabapin 300 Research

The most significant research limitation is the general lack of long-term, controlled data beyond the initial short-term trial periods, especially regarding the durability of response for chronic conditions. Comparative evidence against all available treatments remains limited. Data for certain groups, such as very young children, pregnant individuals, and those with various specific organ impairments, remain insufficient. Research is ongoing to address these evidence gaps and contribute to the broader evidence landscape.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE) Guideline: Neuropathic pain in adults: pharmacological management in non-specialist settings

Common questions about Gabapin 300 (FAQ)

---

Q: Is Gabapin 300 safe for pregnant or breastfeeding women?

A: Regulatory documents state that based on animal studies, there may be a risk of fetal harm associated with its use during pregnancy. There are currently no sufficient, controlled studies in pregnant women. Regarding breastfeeding, the active ingredient is known to pass into human milk. The potential effects of this exposure on a breastfed infant are not fully established, and official information notes that the risks and benefits should be weighed.

---

Q: Is Gabapin 300 eliminated by the kidneys?

A: Yes, according to regulatory information, Gabapin 300 is eliminated from the body almost entirely by the kidneys (renal excretion). The drug is excreted as the unchanged substance and is not significantly broken down (metabolized) by the liver. Because of this, the rate at which the drug is cleared is directly related to a person's kidney function.

---

Q: Are there any dietary restrictions while taking Gabapin 300?

A: Official instructions indicate that the capsules can be taken with or without food and there are no general dietary restrictions. The main administration constraint is related to certain medications: official instructions state that when antacids containing aluminum or magnesium are used, Gabapin 300 must be administered at least two hours later to ensure proper absorption.

---

Q: What is the maximum daily dose of Gabapin 300 for adults?

A: Regulatory documents define the maximum total daily dose for the immediate-release formulation in adults as 3600 mg per day. This total amount is typically administered in divided doses, as detailed in the official prescribing information.

---

Q: Can Gabapin 300 cause sexual side effects?

A: Official labeling states that some adverse reactions concerning sexual function have been reported in clinical trials, including reports of impotence (difficulty achieving an erection). While these events were generally reported infrequently, they are noted in the drug's safety profile, alongside other sexual side effects reported through postmarketing experience.

Storage and Disposal of Gabapentin 300 mg

Gabapentin 300 mg capsules must be stored according to regulatory requirements to ensure product quality and safety.

Storage Requirements

The medication must be stored at a Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The capsules must be kept in a tight and child-resistant container and protected from both moisture and light. It is mandatory to store the medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Gabapentin must be disposed of properly. The preferred method is through an official medicine take-back program. If this is not available, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. Do not flush the capsules down the toilet or pour them down a drain.